Nemaura Medical Inc. Stock

Equities

NMRD

US6404422080

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets 02:04:20 2024-06-07 pm EDT 5-day change 1st Jan Change
0.0464 USD +0.87% Intraday chart for Nemaura Medical Inc. -4.33% -78.81%
Sales 2024 * 200K Sales 2025 * 1.4M Capitalization 1.87M
Net income 2024 * -9M Net income 2025 * -12M EV / Sales 2024 * 9.36 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.34 x
P/E ratio 2024 *
-0.15 x
P/E ratio 2025 *
-0.11 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.38%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.87%
1 week-4.33%
Current month-4.33%
1 month+39.34%
3 months-39.74%
6 months-77.90%
Current year-78.81%
More quotes
1 week
0.05
Extreme 0.046
0.05
1 month
0.03
Extreme 0.031
0.06
Current year
0.03
Extreme 0.0292
0.21
1 year
0.03
Extreme 0.0292
1.25
3 years
0.03
Extreme 0.0292
16.02
5 years
0.03
Extreme 0.0292
17.40
10 years
0.03
Extreme 0.0292
96.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 13-12-23
Chief Operating Officer 47 22-01-04
Chief Tech/Sci/R&D Officer 53 -
Members of the board TitleAgeSince
Chief Executive Officer 50 13-12-23
More insiders
Date Price Change Volume
24-06-07 0.0464 +0.87% 7,246
24-06-06 0.046 0.00% 433
24-06-05 0.046 -8.00% 637
24-06-04 0.05 +8.70% 2,457
24-06-03 0.046 -5.06% 1,053

Delayed Quote OTC Markets, June 07, 2024 at 02:04 pm EDT

More quotes
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0464 USD
Average target price
1.5 USD
Spread / Average Target
+3,132.76%
Consensus